Diffuse Lung Disease
-
Session addresses complex pulmonary vascular challenges in cirrhosis
Yu Kuang (Julie) Lai, MD, detailed the diagnosis of hepatopulmonary syndrome and post-liver transplant hypoxemia during the session, which also reviewed portopulmonary hypertension.
-
Radiologists, pulmonologists to discuss identification of interstitial lung abnormalities
Joe Mammarappallil, MD, PhD, will chair a Monday afternoon session on the recognition and risk stratification of ILAs, including how to differentiate imaging red herrings from findings that point toward progressive fibrosis.
-
90th anniversary sessions to reflect on past, present, and future of field
Nichole T. Tanner, MD, MSCR, FCCP, and five other CHEST experts will chair special sessions about 90 years of progress in mechanical ventilation, TB, lung cancer, diffuse lung disease, respiratory vaccines, and asthma.
-
Panel to outline growing impact of climate change in critical care
Stephanie Maximous, MD, MS, will chair a Sunday morning session on climate change’s growing encroachments in critical illness and acute conditions such as heart attacks, strokes, and asthma exacerbations.
-
Speakers to discuss crucial distinctions of familial, sporadic ILDs
Mary Beth Scholand, MD, FCCP, will serve as co-chair of a Sunday afternoon session on current practices in assessing familial and sporadic ILD patients with telomere measurements and genetic testing.
-
Lung transplantation experts to discuss growing possibilities for patients
Anupam Kumar, MD, FCCP, will chair a Wednesday session on controversies and opportunities that have emerged in the field of lung transplantation in recent years.
-
CHEST grant recipient reflects on completed project in streamlining ILD diagnoses
With her project complete, Kavitha Selvan, MD, shares how the quality improvement grant from CHEST through the Bridging Specialties®: Timely Diagnosis for ILD program has impacted patient care, affected providers, and supported her growth as a clinician.
-
Study identifies key environmental exposures associated with risk of interstitial lung disease
Bradford C. Bemiss, MD, MSc, said the findings underscore the importance of asking patients about potential workplace inhalation exposures.
-
The respiratory toll of traffic pollution in obstructive lung disease and ILD
Traffic-related air pollution reduces lung function and worsens cases of COPD and ILD. Pulmonologists should assess patient exposure and advise on mitigation strategies.
-
Nerandomilast opens the door for potential monotherapy, add-on therapy for pulmonary fibrosis
Positive results from the FIBRONEER trials of nerandomilast in IPF and PPF have sent the phosphodiesterase 4B inhibitor to the FDA for marketing approval. If approved, nerandomilast would be the first new antifibrotic agent for ILD in more than a decade.
-
Optimizing lung transplant care
In the evolving landscape of transplant medicine, APPs are proving to be indispensable through their clinical expertise, consistency, and adaptability across care settings.
-
Current standards in donor lung procurement and preservation
Review the American Association for Thoracic Surgery’s expert consensus guidelines for improving standardization in key areas of lung acquisition.
